The effect of mogamulizumab on the aberrant T cell population in the peripheral blood - A monocentric retrospective analysis

J Dtsch Dermatol Ges. 2023 Sep;21(9):992-1002. doi: 10.1111/ddg.15144. Epub 2023 Jul 3.

Abstract

Background and objectives: The effect of mogamulizumab in cutaneous T-cell lymphoma (CTCL) on T cells (TC) in the peripheral blood and its potential role to navigate treatment intervals are explored.

Methods: We investigated within a retrospective monocentric analysis the effect of mogamulizumab on the CD3+ TC and the aberrant T cell population (TCP), i.e., the CD4+ /CD7- and the CD4+ /CD26- TC, analyzed by flow cytometry.

Results: Thirteen patients with CTCL were included. After four cycles there was a mean reduction of 57% in CD3+ TC, 72% in the CD4+ /CD7- and 75% in the CD4+ /CD26- TCP compared to the individual baseline of each patient. The reduction in CD4+ /CD7+ and CD4+ /CD26+ TC was lower, averaging 54% and 41%. A significant decrease in aberrant TCP was already evident after the first administration. A median plateau of TCP already occurred during the IP. Progressive disease occurred in 5/13 patients without a clear correlation to aberrant TCP.

Conclusions: Already after one dose of mogamulizumab, aberrant TCP and, to a lesser extent, normal TC decrease. We did not observe a clear correlation between TCP and the efficacy of mogamulizumab, but further studies with larger numbers of patients are needed.

Keywords: Mogamulizumab; Mycosis fungoides; Sézary syndrome.

MeSH terms

  • Dipeptidyl Peptidase 4 / analysis
  • Dipeptidyl Peptidase 4 / metabolism
  • Dipeptidyl Peptidase 4 / therapeutic use
  • Humans
  • Lymphoma, T-Cell, Cutaneous*
  • Mycosis Fungoides* / pathology
  • Retrospective Studies
  • Sezary Syndrome*
  • Skin Neoplasms* / drug therapy
  • Skin Neoplasms* / pathology
  • T-Lymphocytes / metabolism

Substances

  • Dipeptidyl Peptidase 4
  • mogamulizumab